Table 1.
Demographics, laboratory values, medications, and performance measuresComp: Bottom align THs. Top align TB entries across row. No internal rules. TB col 1: Indent overruns. Stet sublevel entry indents. TB col 5: Delete all p = and zero before decimal (see row 1) pls.
| SNC (n = 10) | Low CPE cART (n = 12) | High CPE Cart (n = 12) | P value | |
|---|---|---|---|---|
| Demographics | ||||
| Age (years old) | 46±4 | 44±2 | 47±2 | p=0.24 |
| Education (Years) | 14±1 | 14±1 | 15±1 | p=0.78 |
| Males (%) | 60 | 67 | 75 | p=0.42 |
| Caucasian (%) | 40 | 33 | 42 | p=0.56 |
| Laboratory values | ||||
| Median CD4 (cells/μl) | NA | 386±77 | 350±31 | p=0.11 |
| Median log plasma viral load (IQRs) | NA | 2.88 (1.70–3.65) | 2.33 (2.15–2.67) | p=0.13 |
| % Virological suppression | NA | 25% | 25% | p=0.92 |
| Hematocrit (%) | NA | 40±1 | 40±1 | p=0.98 |
| Hematocrit (%) | NA | 40±1 | 40±1 | p=0.97 |
| Medications | ||||
| Composition: | NA | |||
| % PI | 50 | 42 | p=0.53 | |
| % NRTI | 66 | 83 | p=0.21 | |
| % NNRTI | 33 | 42 | p=0.47 | |
| Duration of therapy (months) | NA | 18±3 | 22±4 | p=0.10 |
| Performance measures | ||||
| Global deficit score | 0.3±0.1 | 1.0±0.3 | 0.9±0.3 | *p=0.02 |
| Composition: | NA | |||
| % NN | 33 | 42 | p=0.59 | |
| % MND | 33 | 25 | p=0.42 | |
| % HAD | 33 | 33 | p=0.88 | |
| Mean squeeze pressure (lbs/in2) | 0.85±0.06 | 0.91±0.03 | 0.89±0.03 | p=0.67 |
Note. cART, combination antiretroviral therapy; CNS, central nervous system; CPE, CNS penetration effectiveness; HAD, HIV-associated dementia; IQR, interquartile values; NA, not available; NN, neuropsychologically normal; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; MND, mild neurocognitive disease; PI, protease inhibitor; SNC, seronegative controls. Mean±standard error.
A significant difference in GDS was seen for SNCs compared to low- or high-CPE cART groups.